The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or SGLT-2 (sodium-glucose cotransporter-2) inhibitor. The study will last about 46 weeks and may include up to 20 visits.
Conditions
- Type 2 Diabetes
Intervention
- Orforglipron
- Placebo
Principal Investigator
- Peters, Warren
Sponsor
- Eli Lilly
*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/18/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.
Request Information
Complete the form below to contact the study team and receive more information about this trial.